SYK Stryker (SYK) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000310764
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
1,107
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $3.6M priced
What the filings say about SYK
Insiders, 180 days
-$218.9M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-07-22
Planned sales (Form 144), 90 days
$117.5M
2 notices
Stryker insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, STRYKER CORP insiders sold a net $218.9M of stock across 216 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.2% of the 6,102 shares held after it.
- 2 other insiders sold within 30 days.
- 1,107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Crotty Dylan Bram sold about $144.9K of SYK on Aug 21, 2026; 2 other insiders sold within 30 days and 1,107 funds added in the latest 13F quarter.Context
- 117 earlier Form 4 trades (code P or S) here by this insider (117 sales), the last on Aug 18, 2026.
- The trade is 0.0% of the 2,301,335 shares held after it.
- 2 other insiders sold within 30 days.
- 1,107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STRYKER RONDA E sold about $13.3K of SYK on Aug 19, 2026; 2 other insiders sold within 30 days and 1,107 funds added in the latest 13F quarter.Context
- 117 earlier Form 4 trades (code P or S) here by this insider (117 sales), the last on Aug 18, 2026.
- The trade is 0.0% of the 2,300,895 shares held after it.
- 2 other insiders sold within 30 days.
- 1,107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STRYKER RONDA E sold about $146.6K of SYK on Aug 19, 2026; 2 other insiders sold within 30 days and 1,107 funds added in the latest 13F quarter.Context
- 117 earlier Form 4 trades (code P or S) here by this insider (117 sales), the last on Aug 18, 2026.
- The trade is 0.0% of the 2,300,695 shares held after it.
- 2 other insiders sold within 30 days.
- 1,107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STRYKER RONDA E sold about $66.8K of SYK on Aug 19, 2026; 2 other insiders sold within 30 days and 1,107 funds added in the latest 13F quarter.Context
- 117 earlier Form 4 trades (code P or S) here by this insider (117 sales), the last on Aug 18, 2026.
- The trade is 0.0% of the 2,300,615 shares held after it.
- 2 other insiders sold within 30 days.
- 1,107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STRYKER RONDA E sold about $26.8K of SYK on Aug 19, 2026; 2 other insiders sold within 30 days and 1,107 funds added in the latest 13F quarter.216 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$218.9M over 180 days
-$118.2M over 90 days
below 99% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
1,107 funds bought in last quarter
the highest in Medical Devices
Revenue
+11.2% year over year
more than 53% of Medical Devices
Margin
12.9% net margin
more than 85% of Medical Devices
Buybacks
no share repurchases reported
Short interest
1.6% of the float short (float per yahoo 2026-10-26) · 2.0 days to cover · settled 2026-09-30
below 69% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SYK
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-20.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SYK: institutional holders (13F)
13F holdings, latest reported quarter
27,414,742 sh
$8.6B
22,536,843 sh
$7.1B
17,260,943 sh
$5.7B
15,532,565 sh
$4.9B
15,228,545 sh
$4.8B
Congress trades in SYK
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-07-22 · disclosed 27 days later
$1,001 - $15,000
Sold 2026-06-02 · disclosed 43 days later
$1,001 - $15,000
Sold 2026-01-23 · disclosed 27 days later
$15,001 - $50,000
Bought 2025-12-10 · disclosed 33 days later
$1,001 - $15,000
Sold 2025-11-20 · disclosed 29 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SYK planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Debra King
Filed 2026-08-18
$277.8K
STRYKER RONDA E
Filed 2026-08-17
$117.2M
SYK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Medical Devices ETF
$351.9M position · as of 2026-06-30
11.6%
FAM DIVIDEND FOCUS FUND
$33.7M position · as of 2026-06-30
5.3%
The Jensen Quality Growth Fund Inc
$129.7M position · as of 2026-05-31
4.4%
VALUE LINE ASSET ALLOCATION FUND INC
$13.0M position · as of 2026-06-30
4.3%
AB Concentrated Growth Fund
$20.4M position · as of 2026-06-30
4.3%
Select Medical Technology and Devices Portfolio
$124.5M position · as of 2026-05-31
4.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
STRYKER BED PURCHASE FOR ROCKY MOUNTAIN REGIONAL VA MEDICAL CENTER · 2023-06-02
$3.2M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Mr. Lobo
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$21.4M
$24.8M
$4.6M
+51%
+48%
2024
$22.0M
$48.2M
$6.4M
+53%
+29%
2023
$20.8M
$42.5M
$6.1M
+26%
+26%
2022
$18.6M
$11.4M
$5.2M
+2%
+24%
2021
$16.4M
$27.8M
$5.8M
+10%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $218.9M sold by insiders over 180 days, 1,107 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $117.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
SYK financials
Revenue growth
+11.2%
XBRL, annual
Net margin
12.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$25.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SYK
| FY Dec 2025 | $25.1B |
| FY Dec 2024 | $22.6B |
| FY Dec 2023 | $20.5B |
| FY Dec 2022 | $18.4B |
| FY Dec 2021 | $17.1B |
| Jun 2026 | $6.6B |
| Mar 2026 | $6.0B |
| Dec 2025 | $7.2B |
| Sep 2025 | $6.1B |
| Jun 2025 | $6.0B |
| Mar 2025 | $5.9B |
| Dec 2024 | $6.4B |
| Sep 2024 | $5.5B |
At each fiscal year end
Single quarter
Net margin, TTM
+14.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SYK
| FY Dec 2025 | +12.9% |
| FY Dec 2024 | +13.2% |
| FY Dec 2023 | +15.4% |
| FY Dec 2022 | +12.8% |
| FY Dec 2021 | +11.7% |
| Jun 2026 | +19.4% |
| Mar 2026 | +12.4% |
| Dec 2025 | +11.8% |
| Sep 2025 | +14.2% |
| Jun 2025 | +14.7% |
| Mar 2025 | +11.1% |
| Dec 2024 | +8.5% |
| Sep 2024 | +15.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.7B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SYK
| FY Dec 2025 | $4.3B |
| FY Dec 2024 | $3.5B |
| FY Dec 2023 | $3.1B |
| FY Dec 2022 | $2.0B |
| FY Dec 2021 | $2.7B |
| Jun 2026 | $1.1B |
| Mar 2026 | $415.0M |
| Dec 2025 | $1.9B |
| Sep 2025 | $1.4B |
| Jun 2025 | $928.0M |
| Mar 2025 | $127.0M |
| Dec 2024 | $1.7B |
| Sep 2024 | $1.3B |
At each fiscal year end
Single quarter
Debt to equity
0.62x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity SYK
| FY Dec 2025 | 0.71x |
| FY Dec 2024 | 0.66x |
| FY Dec 2023 | 0.70x |
| FY Dec 2022 | 0.79x |
| FY Dec 2021 | 0.84x |
| Jun 2026 | 0.62x |
| Mar 2026 | 0.64x |
| Dec 2025 | 0.71x |
| Sep 2025 | 0.76x |
| Jun 2025 | 0.78x |
| Mar 2025 | 0.80x |
| Dec 2024 | 0.66x |
| Sep 2024 | 0.77x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.37x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt SYK
| FY Dec 2025 | 0.32x |
| FY Dec 2024 | 0.31x |
| FY Dec 2023 | 0.29x |
| FY Dec 2022 | 0.20x |
| FY Dec 2021 | 0.26x |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.37x |
| Dec 2025 | 0.32x |
| Sep 2025 | 0.29x |
| Jun 2025 | 0.29x |
| Mar 2025 | 0.26x |
| Dec 2024 | 0.31x |
| Sep 2024 | 0.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+16.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SYK
| FY Dec 2025 | +15.1% |
| FY Dec 2024 | +15.3% |
| FY Dec 2023 | +18.0% |
| FY Dec 2022 | +15.0% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | +16.5% |
| Mar 2026 | +15.2% |
| Dec 2025 | +15.1% |
| Sep 2025 | +14.0% |
| Jun 2025 | +14.3% |
| Mar 2025 | +14.3% |
| Dec 2024 | +15.3% |
| Sep 2024 | +18.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SYK
| FY Dec 2025 | +7.1% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +8.2% |
| FY Dec 2022 | +6.6% |
| FY Dec 2021 | +5.8% |
| Jun 2026 | +7.9% |
| Mar 2026 | +7.2% |
| Dec 2025 | +7.1% |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.8% |
| Mar 2025 | +6.7% |
| Dec 2024 | +7.2% |
| Sep 2024 | +8.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.6%
operating income after a 27.6% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital SYK
| FY Dec 2025 | +10.5% |
| FY Dec 2024 | +10.6% |
| FY Dec 2023 | +11.9% |
| FY Dec 2022 | +9.5% |
| FY Dec 2021 | +9.6% |
| Jun 2026 | +11.6% |
| Mar 2026 | +10.6% |
| Dec 2025 | +10.5% |
| Sep 2025 | +9.5% |
| Jun 2025 | +9.0% |
| Mar 2025 | +8.8% |
| Dec 2024 | +10.6% |
| Sep 2024 | +11.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+13.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SYK
| FY Dec 2025 | +13.0% |
| FY Dec 2024 | +11.0% |
| FY Dec 2023 | +12.4% |
| FY Dec 2022 | +9.4% |
| FY Dec 2021 | +8.7% |
| Jun 2026 | +13.8% |
| Mar 2026 | +12.8% |
| Dec 2025 | +13.0% |
| Sep 2025 | +9.7% |
| Jun 2025 | +10.2% |
| Mar 2025 | +10.1% |
| Dec 2024 | +11.0% |
| Sep 2024 | +13.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
31.72x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing SYK
| FY Dec 2025 | 41.84x |
| FY Dec 2024 | 46.40x |
| FY Dec 2023 | 36.30x |
| FY Dec 2022 | 39.63x |
| FY Dec 2021 | 51.33x |
| Jun 2026 | 32.63x |
| Mar 2026 | 38.03x |
| Dec 2025 | 41.84x |
| Sep 2025 | 48.58x |
| Jun 2025 | 52.40x |
| Mar 2025 | 50.30x |
| Dec 2024 | 46.40x |
| Sep 2024 | 38.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$129.0B
market value at close 2026-10-26 on 2026-06-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SYK
| FY Dec 2025 | $146.3B |
| FY Dec 2024 | $147.2B |
| FY Dec 2023 | $123.8B |
| FY Dec 2022 | $103.7B |
| FY Dec 2021 | $110.4B |
| Jun 2026 | $132.3B |
| Mar 2026 | $137.8B |
| Dec 2025 | $146.3B |
| Sep 2025 | $154.7B |
| Jun 2025 | $165.5B |
| Mar 2025 | $156.7B |
| Dec 2024 | $147.2B |
| Sep 2024 | $149.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield SYK
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | +2.8% |
| FY Dec 2022 | +2.2% |
| FY Dec 2021 | +2.7% |
| Jun 2026 | +3.9% |
| Mar 2026 | +3.6% |
| Dec 2025 | +3.2% |
| Sep 2025 | +2.9% |
| Jun 2025 | +2.7% |
| Mar 2025 | +2.5% |
| Dec 2024 | +2.5% |
| Sep 2024 | +2.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.14x
P/E over trailing EPS growth of 28%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing SYK
| FY Dec 2025 | 5.07x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 1.08x |
| FY Dec 2022 | 2.15x |
| FY Dec 2021 | 2.13x |
| Jun 2026 | 1.17x |
| Mar 2026 | 2.27x |
| Dec 2025 | 5.07x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 1.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $25.1B | $22.6B | $20.5B | $18.4B |
| Gross profit | $16.1B | $14.4B | $13.1B | $11.6B |
| Operating income | $4.9B | $3.7B | $3.9B | $2.8B |
| Net income | $3.2B | $3.0B | $3.2B | $2.4B |
| EPS (diluted) | 8.40 | 7.76 | 8.25 | 6.17 |
| Operating cash flow | $5.0B | $4.2B | $3.7B | $2.6B |
| Cash | $4.0B | $3.7B | $3.0B | $1.8B |
| Long-term debt | $14.9B | $12.2B | $10.9B | $11.9B |
| Dividends paid | $1.3B | $1.2B | $1.1B | $1.1B |
SEC XBRL, fiscal years, as known on 2026-10-27
SYK Stock Sonar score 6/7 axes
Find similar shapesCompareSYK ranks highest on profitability (77th percentile) and institutional and government (75th), and lowest on insider conviction (1st), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SYK filings, in plain words
Are Stryker insiders buying or selling SYK?
In the 180 days to 2026-10-27, Stryker insiders were net sellers, a net $218.9M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded SYK?
Yes. In the year to 2026-10-27, 1 House member disclosed buying SYK and 1 House member disclosed selling it; the latest on record is a sale by Thomas H. Kean dated 2026-07-22.
Are there planned insider sales of SYK?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $117.5M of stock; the latest, by Debra King, was filed 2026-08-18.
Read the full summary
In the 180 days to 2026-10-27, Stryker insiders were net sellers of SYK, a net $218.9M across purchases and sales reported on Form 4 by 5 sellers. None of the 36 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 1 member of Congress disclosed buying SYK and 1 member disclosed selling it; the latest on record is a sale by Thomas H. Kean dated 2026-07-22. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $117.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
